With the first and only available sensing technology in deep brain stimulation (DBS), the Percept™ PC device ushers in a new era of DBS therapy for Parkinson’s disease, essential tremor, dystonia,* obsessive-compulsive disorder (OCD),* and epilepsy.DOWNLOAD BROCHURE
Personalize DBS therapy for your patients using objective data combined with event capturing.
The Percept™ PC device features BrainSense™ technology designed to capture brain signals (local field potential, or LFP) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic.†
You can correlate these brain signals with stimulation and events capturing medication, symptoms, or side effects — to deliver personalized, data-driven treatment and adjust as patients' needs evolve.‡
Easy-to-Adjust Stimulation Options
The DBS patient programmer is enhanced so patients can more easily and conveniently engage with their therapy.
Assign custom names to therapy groups so that patients can easily adjust their therapy to their desired activities.
Configure up to four custom events — such as medication adherence, side effects, and experiencing on/off state — that your patients can capture digitally using the intuitive patient programmer.
The Percept™ PC device adds full-body§ 3T MRI eligibility for DBS patients, so they may benefit from the cutting-edge medical imaging when they need it. Plus, using a bipolar therapy group allows therapy to be ON during an MRI scan.
Now clinicians can use MRI Eligibility workflow on the clinician programmer to check MRI eligibility, generate an eligibility report, and place a patient’s device into the appropriate state for an MRI exam.
Patients can use MRI Mode on their patient programmer for a streamlined path to conditionally safe‡‡ MRI scans§, without needing to visit the clinician managing their DBS therapy.
The expanded MRI eligibility of the Percept™ PC device supports the most prevalent and fastest-growing MRI modalities.1
Estimated Global MRI Systems Market:
Percept™ PC device is smaller and thinner than the previous generation Activa™ PC device, and features a modern, ergonomic design — offering enhanced comfort for patients.
Percept™ PC device is smaller yet offers improved longevity.
Plus, its smart battery technology provides real-time prediction of remaining battery life,# so you and your patients can have elevated peace of mind when planning for a replacement device.
The Percept™ PC device features our most advanced DBS technologies: proprietary cortex chipset, custom cutting-edge electronics, and embedded software for patented processing and analysis of brain signals.
The state-of-the-art Percept™ PC device is also designed to facilitate expanded capabilities in the future via software upgrades — so you’re prepared for what’s next in DBS.
Humanitarian Device: The effectiveness of this device for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.
Signals may not be present or measurable in all patients.
Clinical benefits of brain sensing have not been established.
Medtronic DBS systems are MR Conditional, and safe in the MR environment as long as certain conditions are met. If the conditions are not met, a significant risk is tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury including coma, paralysis, or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems for a complete list of conditions: http://professional.medtronic.com/mri.
In overall device volume.
Refers to case thickness.
For median energy use in DBS for patients with Parkinson’s disease, with moderate (up to 2 months per year) BrainSense™ technology usage.
For median energy use in DBS for patients with Parkinson’s disease, with equivalent settings and no BrainSense™ technology usage.
Based on current actual battery level and therapy settings from last seven days.
Under certain conditions.
BCC Research Report HLC078D: Medical Magnetic Resonance Imaging (MRI) Technologies and Global Markets (July 2018).